BACKGROUND: Inhaled @entity230 such as @entity5023 and @entity2715 play a central role in the treatment of @entity565 . @entity5023 exhibits excellent clinical effectiveness; however, oral adverse effects can occur. OBJECTIVE: To compare the frequency of @entity5253 in @entity748 @entity1 treated with @entity5023 and @entity2715 , to evaluate the effect of gargling with @entity2379 , and to measure the inhalation flow rate on @entity7553 . METHODS: The study consisted of 143 @entity748 @entity1 who were treated with inhaled @entity230 , 11 @entity748 @entity1 not treated with inhaled @entity230 , and 86 healthy volunteers. Quantitative fungal culture was performed by aseptically obtaining a retropharyngeal wall swab from these @entity1 . @entity1 with positive results were treated with gargling using a 1:50 dilution @entity2379 solution. In @entity748 @entity1 treated with @entity5023 , the inhalation flow rate was measured using an inspiratory flow meter. RESULTS: The amount of Candida spp. was significantly greater in @entity748 @entity1 taking inhaled @entity230 compared with those who were not. It was also significantly greater in @entity1 with oral symptoms than asymptomatic @entity1 and significantly greater in @entity748 @entity1 treated with @entity5023 than in those treated with @entity2715 . Although the presence of Candida did not correlate with the inhaled dose of @entity2715 , it did increase with the dose of @entity5023 . Gargling with @entity2379 was effective in most @entity748 @entity1 with @entity7553 . Candidiasis was not due to inappropriate flow rates during inhalation of @entity230 . CONCLUSIONS: Fungal culture of a retropharyngeal wall swab may be useful for predicting the risk of developing @entity5253 in @entity748 @entity1 treated with inhaled @entity230 . The amount of isolated Candida was significantly greater in @entity748 @entity1 treated with @entity5023 than in those treated with @entity2715 . Attention to dosage is required as the amount of Candida increased with dose of @entity5023 . Gargling with a 1:50 dilution of @entity2379 is effective in treating @entity5253 of @entity748 @entity1 treated with inhaled @entity230 .

@entity5253 associated with inhaled corticosteroid use: comparison of XXXX and @entity2715 .

@entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity5253 :: ('MESH:D002180', 'Disease') :: ['oral candidiasis'] @entity2715 :: ('MESH:D001507', 'Chemical') :: ['beclomethasone dipropionate', 'beclomethasone'] @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B'] @entity565 :: ('MESH:D001249', 'Disease') :: ['bronchial asthma'] @entity7553 :: ('MESH:D002177', 'Disease') :: ['candidiasis'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity5023 :: ('MESH:C065382', 'Chemical') :: ['Fluticasone', 'fluticasone propionate', 'fluticasone']
@entity5023 :: (MESH:C065382,Chemical) :: ['fluticasone']
